Anti-third party CD8+ CTLs as potent veto cells: Coexpression of CD8 and FasL is a prerequisite

Immunity

Volumn 13, Issue 4, 2000, Pages 507-515

  Reich Zeliger, S S ^a   Zhao, Y Y ^a   Krauthgamer, R R ^a   Bachar Lustig, E E ^a   Reisner, Y Y ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; FAS ANTIGEN; FAS LIGAND;

ANIMAL CELL; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GRAFT VERSUS HOST REACTION; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; VETO CELL;

EID: 0033680730     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-7613(00)00050-9     Document Type: Article

References (58)

1. Immunoregulatory role of CD8α in the veto effect. Transforming growth factor-β1 activation
2. b:conversion of helper-independent to helper-dependent CTL
3. Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum
4. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype
5. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
6. Induction of donor-type chimerism and transplantation tolerance across major histocompatibility barriers in sublethally irradiated mice by sca-1(+)Lin(-) bone marrow progenitor cells: Synergism with non-alloreactive (host x donor)F(1) T cells
7. Bone marrow transplantation across major genetic barriers: The role of 'mega' dose stem cells and non-alloreactive T cells in donor anti3rd party CTLs
8. + cytotoxic effector T cells. Peptide-induced paralysis affects the peptide-MHC-recognizing cytotoxic T lymphocytes and is independent of Fas/Fas ligand interactions
9. The Fas-based mechanism of lymphocytotoxicity
10. Regulation of the cytotoxic T lymphocyte response against Qa-1 alloantigens
11. Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T cells in an H-2 haplotype disparate mouse combination
12. Veto cell H-2 antigens: Veto cell activity is restricted by determinants encoded by K, D, and I MHC regions
13. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. I. CTL clones express strong anti-self suppressive activity
14. Antiself suppressive (veto) activity of responder cells in mixed lymphocyte cultures
15. Functional heterogeneity in allospecific cytotoxic T lymphocyte clones. III. Direct correlation between development of syngeneic cytotoxicity and loss of veto activity; implications for the mechanism of veto action
16. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
17. Enhancemerit of BM allografting from C57BL/6 'nude' mice into C3H/HeJ recipients by tolerized T cells from (C57BL/6→C3H/HeJ) and (C3H/HeJ→C57BL/6) chimeras
18. Studies on the mechanism of suppression of primary cytotoxic responses by cloned cytotoxic T lymphocytes
19. Cloned cytolytic T cells can suppress primary cytotoxic responses directed against them
20. Veto cells
21. An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow
22. Cytotoxic T lymphocytes to endogenous mouse retroviruses and mechanisms of retroviral escape
23. Complete blockade of B7 family-mediated costimulation is necessary to induce human alloantigen-specific anergy: A method to ameliorate graft-versus-host disease and extend the donor pool
24. Clonal deletion of postthymic T cells: Veto cells kill precursor cytotoxic T lymphocytes
25. Inhibition of death receptor signals by cellular FLIP
26. Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells
27. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells
28. Wheat germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have potent natural suppressor activity
29. Clonal deletion of postthymic T cells: Veto cells kill precursor cytotoxic T lymphocytes
30. Induction of T cell anergy by low numbers of agonist ligands
31. Booster irradiation to the spleen following total body irradiation: A new immunosuppressive approach for allogeneic bone marrow transplantation
32. Enhancement by dimethyl myleran of donor type chimerism in murine recipients of bone marrow allografts
33. Enhancement of bone marrow allografts from nude mice into mismatched recipients by T cells void of graft-versus-host activity
34. + thymocytes
35. The regulation of CD95 ligand expression and function in CTL
36. An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it
37. Use of retroviral vectors for gene transfer and expression
38. Thy 1+ donor cells function as veto cells in the maintenance of tolerance across a major histocompatibility complex disparity in mixed-lymphoid radiation chimeras
39. Do donor cells function as veto cells in the induction and maintenance of tolerance across an MHC disparity in mixed lymphoid radiation chimeras?
40. Hybrid antibody mediated veto of cytotoxic T lymphocyte responses
41. Tolerance induction by 'megadose' hematopoietic transplants: Donor-type human CD34 stem cells induce potent specific reduction of host anti-donor cytotoxic T lymphocyte precursors in mixed lymphocyte culture
42. Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen
43. Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells
44. The role of megadose CD34+ progenitor cells in the treatment of leukemia patients without a matched donor and in tolerance induction for organ transplantation
45. Antiretroviral cytolytic T-lymphocyte nonresponsiveness: FasL/Fas- mediated inhibition of CD4(+) and CD8(+) antiviral T cells by viral antigen-positive veto cells
46. The level of CD8 expression can determine the outcome of thymic selection
47. Programmed cell death of T cells signaled by the T cell receptor and the alpha 3 domain of class I MHC
48. + cells whose class I MHC can bind the peptide
49. Cloned natural suppressor cells prevent lethal graft-vs-host disease
50. Purification and characterization of the Fas-ligand that induces apoptosis
51. Expression of the Fas ligand in cells of T cell lineage
52. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning
53. Veto-like down regulation of T helper cell reactivity in viva by injection of semi-allogeneic spleen cells
54. Veto suppression: The peripheral way of T cell tolerization
55. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation
56. Blockade of multiple costimulatory receptors induces hyporesponsiveness: Inhibition of CD2 plus CD28 pathways
57. In vitro and in vivo activities of long-term cultured veto suppressor clones
58. + cells in the induction of peripheral tolerance